CD47 and breast cancer: Nonetheless, the benefits of modulating the Zeb1 transcriptional/epigenetic network in cancer immunotherapy have been clearly illustrated in the blockade of CD47, a direct transcriptional target of Zeb1, that enhances phagocytosis of breast cancer cells undergoing EMT (72).